Covance enters R&D collaboration

Thursday, January 19, 2012 08:30 AM

Covance, Inserm Transfert, a subsidiary of Inserm, and seed investment company Inserm Transfert Initiative have signed a four-year R&D collaboration.

Covance’s France- and U.K.-based facilities will conduct discovery and early development studies for Inserm, its subsidiary, and startups within Inserm Transfert Initiative’s portfolio. The startups will also gain access to Covance’s scientific, operational and program management expertise.

Covance experts will advise representatives from Inserm Transfert and Inserm Transfert Initiative to help select projects that will most benefit from Covance’s drug discovery and drug development capabilities.

“The robust resources Covance brings will help our startup companies grow more quickly and efficiently,” said Matthieu Coutet, investment director of Inserm Transfert Initiative. “Covance will provide important strategic guidance to help them establish and implement early clinical development plans with the right technical know-how and management support.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs